Cargando…
Effectiveness and Safety of DOACs vs. VKAs in AF Patients With Cancer: Evidence From Randomized Clinical Trials and Observational Studies
Background: The use of direct oral anticoagulants (DOACs) is recommended as the preferred treatment drug in patients with nonvalvular atrial fibrillation (AF). However, the effectiveness and safety of DOACs compared with vitamin K antagonists (VKAs) in patients with cancer and AF are still controver...
Autores principales: | Liu, Fuwei, Xu, Zixuan, Luo, Jun, Yu, Peng, Ma, Jianyong, Yuan, Ping, Zhu, Wengen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602680/ https://www.ncbi.nlm.nih.gov/pubmed/34805320 http://dx.doi.org/10.3389/fcvm.2021.766377 |
Ejemplares similares
-
An Updated Meta-Analysis of DOACs vs. VKAs in Atrial Fibrillation Patients With Bioprosthetic Heart Valve
por: Cao, Yalin, et al.
Publicado: (2022) -
Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis
por: Zeng, Shan, et al.
Publicado: (2022) -
Direct Oral Anticoagulants vs. Warfarin in Latin American Patients With Atrial Fibrillation: Evidence From Four post-hoc Analyses of Randomized Clinical Trials
por: Liu, Fuwei, et al.
Publicado: (2022) -
Post-TAVR patients with atrial fibrillation: are NOACs better than VKAs?—A meta-analysis
por: Wang, Lu, et al.
Publicado: (2023) -
Uninterrupted DOACs Approach for Catheter Ablation of Atrial Fibrillation: Do DOACs Levels Matter?
por: Hardy, Michael, et al.
Publicado: (2022)